Why PTC Therapeutics Is Rocketing 74% Today
IMAGE SOURCE: GETTY IMAGES. What happened After the company reported that it had won support from an influential committee that had been considering whether to renew conditional approval of Translarna, the company’s Duchenne muscular dystrophy drug, PTC Therapeutics (NASDAQ:PTCT) shares are skyrocketing 74% higher at noon EST on Friday. So what Translarna secured conditional EU approval […]Read More